KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Palvella Therapeutics (PVLA) Operating Margin (2016 - 2024)

Palvella Therapeutics has reported Operating Margin over the past 9 years, most recently at 4716.28% for Q3 2022.

  • Quarterly Operating Margin fell 424766.0% to 4716.28% in Q3 2022 from the year-ago period, while the trailing twelve-month figure was 215.64% through Sep 2022, up 2792.0% year-over-year, with the annual reading at 164.97% for FY2021, 2311.0% down from the prior year.
  • Operating Margin was 4716.28% for Q3 2022 at Palvella Therapeutics, up from 5360.87% in the prior quarter.
  • Over five years, Operating Margin peaked at 7.7% in Q4 2019 and troughed at 5360.87% in Q2 2022.
  • The 5-year median for Operating Margin is 130.27% (2021), against an average of 815.67%.
  • Year-over-year, Operating Margin surged 210030bps in 2019 and then crashed -485064bps in 2022.
  • A 5-year view of Operating Margin shows it stood at 2108.0% in 2018, then skyrocketed by 100bps to 7.7% in 2019, then crashed by -10516bps to 817.59% in 2020, then soared by 84bps to 130.27% in 2021, then tumbled by -3520bps to 4716.28% in 2022.
  • Per Business Quant, the three most recent readings for PVLA's Operating Margin are 4716.28% (Q3 2022), 5360.87% (Q2 2022), and 67.86% (Q1 2022).